These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 2452642)
21. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924 [TBL] [Abstract][Full Text] [Related]
22. [Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract]. Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Kunii N; Yamamoto H; Sakurai D; Hanazawa T Arerugi; 2008 May; 57(5):558-61. PubMed ID: 18520178 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Rossi RE; Monasterolo G Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445 [TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Lalek N; Kosnik M; Silar M; Korosec P Clin Exp Allergy; 2010 Aug; 40(8):1186-93. PubMed ID: 20528883 [TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of the human basophil degranulation test in grass pollen allergic patients. Aoki H; Vellieux P; Theobald-Segalen C; Senft M; Vervloet D; Benveniste J; Charpin J Ann Allergy; 1986 Nov; 57(5):319-20. PubMed ID: 3535577 [TBL] [Abstract][Full Text] [Related]
26. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Nagao M; Hiraguchi Y; Hosoki K; Tokuda R; Usui T; Masuda S; Yamaguchi M; Fujisawa T Int Arch Allergy Immunol; 2008; 146 Suppl 1():47-53. PubMed ID: 18504407 [TBL] [Abstract][Full Text] [Related]
27. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. Walker SM; Pajno GB; Lima MT; Wilson DR; Durham SR J Allergy Clin Immunol; 2001 Jan; 107(1):87-93. PubMed ID: 11149996 [TBL] [Abstract][Full Text] [Related]
28. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Powell RJ; Frew AJ; Corrigan CJ; Durham SR Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551 [TBL] [Abstract][Full Text] [Related]
29. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Howarth P; Malling HJ; Molimard M; Devillier P Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377 [TBL] [Abstract][Full Text] [Related]
30. An investigation on in vivo allergenicity of Artemisia annua leaves and stems. Leng X; Ye ST Asian Pac J Allergy Immunol; 1987 Dec; 5(2):125-8. PubMed ID: 3449079 [TBL] [Abstract][Full Text] [Related]
31. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. Colás C; Monzón S; Venturini M; Lezaun A J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938 [TBL] [Abstract][Full Text] [Related]
32. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279 [TBL] [Abstract][Full Text] [Related]
33. Rush immunotherapy with a standardized Bermuda grass pollen extract. Armentia-Medina A; Blanco-Quiros A; Martin-Santos JM; Alvarez-Cuesta E; Moneo-Goiri I; Carreira P; Losada-Cosmes E Ann Allergy; 1989 Aug; 63(2):127-35. PubMed ID: 2669567 [TBL] [Abstract][Full Text] [Related]
34. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy. Czarnecka-Operacz M; Jenerowicz D; Silny W Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104 [TBL] [Abstract][Full Text] [Related]
35. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. Hylander T; Latif L; Petersson-Westin U; Cardell LO J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268 [TBL] [Abstract][Full Text] [Related]
36. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. Wilson DR; Nouri-Aria KT; Walker SM; Pajno GB; O'Brien F; Jacobson MR; Mackay IS; Durham SR J Allergy Clin Immunol; 2001 Jun; 107(6):971-6. PubMed ID: 11398073 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. González P; Florido F; Sáenz de San Pedro B; de la Torre F; Rico P; Martín S J Investig Allergol Clin Immunol; 2002; 12(4):263-71. PubMed ID: 12926186 [TBL] [Abstract][Full Text] [Related]
38. [Desensitization for those afflicted with hay fever. With 4 pricks hyposensitized to pollen]. MMW Fortschr Med; 2004 Mar; 146(11):58. PubMed ID: 15152778 [No Abstract] [Full Text] [Related]
39. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data. Ariano R; Panzani RC; Mistrello G Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297 [TBL] [Abstract][Full Text] [Related]